Marinomed Biotech AG
9
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
11%
1 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye
Role: lead
Carrageenan Nasal Spray for COVID-19 Prophylaxis
Role: collaborator
Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients
Role: lead
Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Role: lead
Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers
Role: lead
Demonstration of an Anti-allergic Effect in Subjects Treated With Callergin Nasal Spray in Comparison to Untreated Subjects and Subjects Treated With Vis Alpin® Alpensalz Nasal Spray, All Suffering From Grass Pollen Induced Rhinitis/Rhinoconjunctivitis
Role: lead
Demonstration of a Decongestant Effect of "Coldamaris Akut" Compared to Saline Nasal Spray.
Role: lead
Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses
Role: lead
Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray
Role: lead
All 9 trials loaded